Investors

Press Releases

ObsEva Announces Third Quarter 2019 Financial Results

November 7, 2019

– Reports Update on Three Women’s Health Product Candidates – – Focusing on Phase 3 Programs for Linzagolix and the…

Read more

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

November 7, 2019

Company to Discontinue Current Nolasiban IVF Program   Geneva, Switzerland and Boston, MA – November 7, 2019 – ObsEva SA (NASDAQ:…

Read more

ObsEva SA to Hold Conference Call to Discuss IMPLANT 4 Trial Results and Third Quarter 2019 Financial and Business Update on November 7, 2019

November 6, 2019

Geneva, Switzerland and Boston, MA –November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

November 6, 2019

Geneva, Switzerland and Boston, MA – November 6, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…

Read more

ObsEva SA to Hold Third Quarter 2019 Financial Results and Business Update Call on November 11, 2019

November 4, 2019

Geneva, Switzerland and Boston, MA –November 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical…

Read more

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

October 31, 2019

FDA Allows IMPLANT 3 Trial to Begin Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV…

Read more

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

October 11, 2019

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…

Read more

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

October 9, 2019

Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage…

Read more

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

September 27, 2019

Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…

Read more

ObsEva announces new composition of its Executive Committee

September 11, 2019

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.